2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Infectious Diseases, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, APL, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5110 Frontline azacitidine, venetoclax and gilteritinib for fit patients with newly diagnosed FLT3-mutated acute myeloid leukemia: A real-world study

Zhang Mengyun, Xiao Han2, Cheng Zhang, MD3, Xi Zhang, MD4, Wen Qin, MD5
1 Xinqiao Hospital Army Medical University, Chongqing, China
2 Xinqiao Hospital Army Medical University, Chongqing, China
3 Xinqiao Hospital Army Medical University, Chongqing, China
4 Xinqiao Hospital Army Medical University, Chongqing, China
5 Xinqiao Hospital Army Medical University, Chongqing, China
Background

FLT3-mutated acute myeloid leukemia (AML) represents a biologically aggressive subtype associated with increased relapse risk and inferior long-term outcomes. Although intensive chemotherapy combined with FLT3 inhibitors remains a standard approach for fit patients, treatment-related toxicity, prolonged cytopenias, and relapse remain significant challenges.The combination of venetoclax (VEN) with FLT3 inhibition has demonstrated synergistic antileukemic activity. Recent studies have demonstrated promising efficacy of azacitidine, venetoclax, and gilteritinib (GVA) in elderly or chemotherapy-ineligible patients with newly diagnosed FLT3-mutated AML.However, the role of GVA as a frontline chemotherapy-sparing induction strategy in fit patients eligible for intensive therapy remains unexplored.We evaluated the efficacy, molecular response, transplant feasibility, and safety of frontline GVA therapy in fit patients with newly diagnosed FLT3-mutated AML.

Methods

This retrospective study included fit patients with newly diagnosed FLT3-mutated AML who received frontline GVA induction at our institution between June 2024 and December 2025.Patients were considered fit for intensive therapy based on age, performance status, organ function, and absence of major comorbidities precluding intensive induction.The treatment regimen consisted of azacitidine (75 mg/m², days 1–7), venetoclax with dose escalation (100 mg day 1, 200 mg day 2, followed by 400 mg daily), and gilteritinib (80 mg daily). Venetoclax duration was adjusted according to bone marrow response and hematologic recovery.Clinical characteristics, molecular profiles, ELN 2022 risk classification, treatment response, measurable residual disease (MRD), allogeneic hematopoietic stem cell transplantation (allo-HSCT), survival outcomes, and adverse events were analyzed.The primary endpoint was composite complete remission (CRc) after the first treatment cycle. MRD was assessed by multiparameter flow cytometry.

Results

14 patients with newly diagnosed FLT3-mutated AML were included. The median age was 58 years (range, 40–63), and 5 patients (35.7%) presented with hyperleukocytosis.FLT3-ITD mutations were detected in 13 patients (92.9%)with median VAF of 0.76 (range,0.18-1.83), and FLT3-TKD mutations in 2 patients (14.3%). Co-occurring mutations included NPM1 mutations (n=4, 28.6%), RAS pathway mutations (n=2, 14.3%), and myelodysplasia-related gene mutations (n=4, 28.6%). According to ELN 2022 classification, 8 patients (57.1%) were intermediate-risk and 6 (42.9%) were adverse-risk.After the first cycle of GVA induction,10 patients (71.4%)achieved complete remission (CR), and 2 patients achieved partial remission (PR), resulting in an overall response rate of 85.7% (12/14). Both patients with PR converted to CR after the second cycle of GVA therapy, resulting in a final CRc rate of 85.7% (12/14).Among the 10 patients achieving CR after cycle 1, MRD negativity was achieved in 7 patients (70.0%) by multiparameter flow cytometry.No 28-day early mortality was observed. Among the 12 patients achieving CRc, 8 patients (66.7%) subsequently proceeded to allo-HSCT after consolidation therapy.After a median follow-up of 9.5 months, median overall survival and progression-free survival were not reached. Four patients had died at the last follow-up, including two patients who did not undergo transplantation.

Conclusions

Frontline azacitidine, venetoclax, and gilteritinib therapy demonstrated promising efficacy in fit patients with newly diagnosed FLT3-mutated AML, achieving high CRc rates, substantial MRD clearance, and acceptable early safety.Importantly, this chemotherapy-sparing induction approach enabled rapid disease control and successful bridging to allo-HSCT in the majority of responders.These findings support further prospective multicenter evaluation of GVA as a potential frontline alternative to intensive chemotherapy for selected fit patients with FLT3-mutated AML.

Zhang Mengyun: No relevant conflicts of interest to declare.